CU20140026A7 - Péptidos horquilla beta con propiedades antivirales contra el virus dengue - Google Patents

Péptidos horquilla beta con propiedades antivirales contra el virus dengue

Info

Publication number
CU20140026A7
CU20140026A7 CUP2014000026A CU20140026A CU20140026A7 CU 20140026 A7 CU20140026 A7 CU 20140026A7 CU P2014000026 A CUP2014000026 A CU P2014000026A CU 20140026 A CU20140026 A CU 20140026A CU 20140026 A7 CU20140026 A7 CU 20140026A7
Authority
CU
Cuba
Prior art keywords
peptides
properties against
antiviral properties
against virus
virus dengue
Prior art date
Application number
CUP2014000026A
Other languages
English (en)
Inventor
Santiago Glay Chinea
Galindo Vivian Huerta
Dunn Alejandro Miguel Martín
Pérez Hilda Elisa Garay
Acosta Osvaldo Reyes
CAMA Viviana FALCÓN
Gómez Dianne Pupo
Díaz Alexis Yero
Perera Gabriel Jesús Márquez
NÚÑEZ Mónica SARRÍA
Cruz Osmany Guirola
Suárez Rocío Garateix
Pérez Karen Álvarez
Blanco Sonia González
Castillo Mariela Vázquez
López Luis Javier González
Original Assignee
Ct De Ingeniería Genética Y Biotecnología Biocubafarma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Ingeniería Genética Y Biotecnología Biocubafarma filed Critical Ct De Ingeniería Genética Y Biotecnología Biocubafarma
Priority to CUP2014000026A priority Critical patent/CU20140026A7/es
Priority to ARP150100549A priority patent/AR099563A1/es
Priority to MYPI2016703158A priority patent/MY181033A/en
Priority to AU2015226580A priority patent/AU2015226580B2/en
Priority to JP2016555504A priority patent/JP6854644B2/ja
Priority to US15/119,058 priority patent/US9896482B2/en
Priority to PCT/CU2015/000002 priority patent/WO2015131858A2/es
Priority to EP15718758.4A priority patent/EP3115056B1/en
Priority to BR112016019672-4A priority patent/BR112016019672B1/pt
Priority to CA2940078A priority patent/CA2940078C/en
Priority to MX2016011420A priority patent/MX363745B/es
Priority to CN201580011814.8A priority patent/CN106132981B/zh
Priority to KR1020167026665A priority patent/KR102325400B1/ko
Priority to ES15718758T priority patent/ES2733648T3/es
Publication of CU20140026A7 publication Critical patent/CU20140026A7/es
Priority to PH12016501715A priority patent/PH12016501715A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención está relacionada con péptidos sintéticos, estructuralmente constreñidos, que han sido optimizados para la formación de estructura horquilla beta. Dichos péptidos son capaces de inhibir o atenuar la infección por el virus Dengue (DENV). La invención incluye también composiciones farmacéuticas que contienen estos péptidos sintéticos, las que son útiles para la prevención y/o el tratamiento de las infecciones causadas por DENV. De igual forma, la invención provee un método de tratamiento de las infecciones causadas por este virus.
CUP2014000026A 2014-03-03 2014-03-03 Péptidos horquilla beta con propiedades antivirales contra el virus dengue CU20140026A7 (es)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CUP2014000026A CU20140026A7 (es) 2014-03-03 2014-03-03 Péptidos horquilla beta con propiedades antivirales contra el virus dengue
ARP150100549A AR099563A1 (es) 2014-03-03 2015-02-24 PÉPTIDOS HORQUILLA b CON PROPIEDADES ANTIVIRALES CONTRA EL VIRUS DENGUE
EP15718758.4A EP3115056B1 (en) 2014-03-03 2015-02-26 Beta-hairpin peptides having anti-viral properties against the dengue virus
CA2940078A CA2940078C (en) 2014-03-03 2015-02-26 Beta hairpin peptides having anti-viral properties against the dengue virus
JP2016555504A JP6854644B2 (ja) 2014-03-03 2015-02-26 デングウイルスに対する抗ウイルス特性を有するベータヘアピンペプチド
US15/119,058 US9896482B2 (en) 2014-03-03 2015-02-26 Beta hairpin peptides having antiviral properties against Dengue virus
PCT/CU2015/000002 WO2015131858A2 (es) 2014-03-03 2015-02-26 Péptidos horquilla beta con propiedades antivirales contra el virus dengue
MYPI2016703158A MY181033A (en) 2014-03-03 2015-02-26 Beta hairpin peptides having antiviral properties against dengue virus
BR112016019672-4A BR112016019672B1 (pt) 2014-03-03 2015-02-26 Peptídeos de grampo beta com propriedades antivirais contra o vírus da dengue, composição farmacêutica e seus usos
AU2015226580A AU2015226580B2 (en) 2014-03-03 2015-02-26 Beta-hairpin peptides having anti-viral properties against the dengue virus
MX2016011420A MX363745B (es) 2014-03-03 2015-02-26 Peptidos horquilla beta con propiedades antivirales contra el virus dengue.
CN201580011814.8A CN106132981B (zh) 2014-03-03 2015-02-26 具有针对登革病毒的抗病毒特性的β-发夹肽
KR1020167026665A KR102325400B1 (ko) 2014-03-03 2015-02-26 뎅기열 바이러스에 대한 항바이러스 속성을 가진 베타 헤어핀 펩타이드
ES15718758T ES2733648T3 (es) 2014-03-03 2015-02-26 Péptidos de horquilla beta que tienen propiedades antivirales contra el virus del Dengue
PH12016501715A PH12016501715A1 (en) 2014-03-03 2016-08-31 Beta hairpin peptides having antiviral properties against dengue virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CUP2014000026A CU20140026A7 (es) 2014-03-03 2014-03-03 Péptidos horquilla beta con propiedades antivirales contra el virus dengue

Publications (1)

Publication Number Publication Date
CU20140026A7 true CU20140026A7 (es) 2015-11-27

Family

ID=53008223

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2014000026A CU20140026A7 (es) 2014-03-03 2014-03-03 Péptidos horquilla beta con propiedades antivirales contra el virus dengue

Country Status (14)

Country Link
US (1) US9896482B2 (es)
EP (1) EP3115056B1 (es)
JP (1) JP6854644B2 (es)
KR (1) KR102325400B1 (es)
CN (1) CN106132981B (es)
AR (1) AR099563A1 (es)
AU (1) AU2015226580B2 (es)
CA (1) CA2940078C (es)
CU (1) CU20140026A7 (es)
ES (1) ES2733648T3 (es)
MX (1) MX363745B (es)
MY (1) MY181033A (es)
PH (1) PH12016501715A1 (es)
WO (1) WO2015131858A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3448415A4 (en) 2016-04-29 2019-11-06 Araim Pharmaceuticals, Inc. TISSUE PROTECTIVE PEPTIDES FOR PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH TISSUE INJURY

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
CU23632A1 (es) * 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.
CU23630A1 (es) * 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
CU20080028A6 (es) * 2008-02-29 2011-02-24 Ct Ingenieria Genetica Biotech Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus

Also Published As

Publication number Publication date
PH12016501715B1 (en) 2016-12-19
AU2015226580A1 (en) 2016-09-15
JP6854644B2 (ja) 2021-04-07
CN106132981A (zh) 2016-11-16
AU2015226580B2 (en) 2018-11-08
ES2733648T3 (es) 2019-12-02
BR112016019672A2 (pt) 2017-10-24
MY181033A (en) 2020-12-16
EP3115056B1 (en) 2019-04-03
EP3115056A2 (en) 2017-01-11
WO2015131858A2 (es) 2015-09-11
PH12016501715A1 (en) 2016-12-19
CN106132981B (zh) 2019-11-12
CA2940078C (en) 2020-11-17
KR20160127097A (ko) 2016-11-02
MX2016011420A (es) 2016-11-16
CA2940078A1 (en) 2015-09-11
AR099563A1 (es) 2016-08-03
WO2015131858A3 (es) 2015-10-29
JP2017509619A (ja) 2017-04-06
US9896482B2 (en) 2018-02-20
US20170152290A1 (en) 2017-06-01
KR102325400B1 (ko) 2021-11-12
MX363745B (es) 2019-04-01

Similar Documents

Publication Publication Date Title
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
CO2018010459A2 (es) Composiciones que comprenden cepas bacterianas
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
PH12017500207A1 (en) Indoles for use in influenza virus infection
SA516370684B1 (ar) مثبطات بوليمراز فيروس الالتهاب الكبدي سي
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
CR20160337A (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b
JO3558B1 (ar) تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
NZ727392A (en) Methods of preparing substituted nucleotide analogs
MA50264A (fr) Méthodes de traitement des infections de type hépatite b
BR112018069974A2 (pt) compostos de tiazolida para o tratamento de infecções virais
CR20160178A (es) Derivados de desoxinojirimicina y sus métodos de uso
ECSP19026702A (es) Compuestos novedosos para el tratamiento de enfermedades parasitarias
CO2020005420A2 (es) Compuestos antibacterianos
PH12016502001A1 (en) Novel bacteriophage and composition comprising same
UY36221A (es) Derivados de isoindolinona
PE20170185A1 (es) Composiciones farmaceuticas para tratar enfermedades infecciosas
CL2016001977A1 (es) Composición que comprende igm derivada de plasma y su uso para el tratamiento o prevención de afecciones inmunitarias.
PH12017500816A1 (en) Long acting pharmaceutical compositions for hepatitis c
PH12016502000A1 (en) Novel bacteriophage and composition comprising same
AR099563A1 (es) PÉPTIDOS HORQUILLA b CON PROPIEDADES ANTIVIRALES CONTRA EL VIRUS DENGUE
EA201790851A1 (ru) Способы предотвращения, уменьшения и лечения макулодистрофии
EA201700097A1 (ru) Пептид для лечения сахарного диабета 2-го типа и его осложнений
EA201301340A1 (ru) Фармацевтическая композиция, обладающая нейропротекторным действием, её применение и способы повышения жизнеспособности и профилактики или лечения цереброваскулярных и нейродегенеративных заболеваний
TH1601005264A (es)